Side Effects of duvelisib: A Synthesis of Findings from 12 Studies

  1. Home
  2. Side Effects of duvelisib
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Side Effects of duvelisib: A Synthesis of Findings from 12 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Side Effects of duvelisib: A Synthesis of Findings from 12 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major Research Findings

Duvelisib is a PI3Kδ/γ inhibitor, approved by the FDA for the treatment of chronic lymphocytic leukemia (CLL) and indolent non-Hodgkin lymphoma. 1 , . It targets the PI3K/AKT/mTOR pathway, which plays a key role in cell growth, survival, and proliferation. 3 . Studies show that duvelisib is effective in treating relapsed or refractory CLL and iNHL. 3 , 5 . However, the drug is associated with potential side effects.

Reasons for Side Effects

Duvelisib’s side effects are primarily related to its mechanism of action, which targets PI3K enzymes involved in various cellular processes, including immune cell function. 7 . As PI3Kδ is crucial for the development and function of regulatory T cells (Treg cells) responsible for immune suppression, inhibiting it can lead to immunosuppression. 7 . Additionally, the drug’s off-target effects on other pathways might contribute to its side effects. 8 .

Common Side Effects

Immunosuppression

Duvelisib can cause immunosuppression due to its inhibition of PI3Kδ and PI3Kγ, which are critical for immune cell function. 3 , 7 . This can increase the risk of infections and potentially lead to autoimmune disorders. 3 , 4 .

Gastrointestinal Side Effects

Duvelisib can cause gastrointestinal side effects like diarrhea, nausea, vomiting, and abdominal pain. , 2 . In severe cases, intestinal perforation might occur. 6 .

Skin Side Effects

Skin side effects like rash, itching, and dryness are also possible with duvelisib. 4 , 2 .

Other Side Effects

Duvelisib can also lead to other side effects like pneumonia, liver dysfunction, and hyperglycemia. 1 , 6 . In addition, the FDA issued a warning about a possible increased risk of death with duvelisib use compared to other treatments. 1 .

Side Effect Management

Immunosuppression

Close monitoring for infections and preventive measures like handwashing and vaccinations are essential for patients on duvelisib. 3 . Regular consultations with healthcare professionals are crucial. 3 .

Gastrointestinal Side Effects

Treating diarrhea might require antidiarrheal medication and dietary adjustments. , 2 .

Skin Side Effects

Consult a doctor if rash or itching occurs to get appropriate medication. 4 .

Comparison between Studies

Commonalities in Studies

Multiple studies have consistently demonstrated the efficacy of duvelisib in treating CLL and iNHL, often showing superior effectiveness compared to other PI3K inhibitors. 3 , 10 , 5 .

Differences in Studies

There are variations in the reported side effects of duvelisib across different studies. 1 . Notably, some studies have raised concerns about a potential increased risk of death associated with duvelisib. 1 .

Precautions for Real-Life Applications

While duvelisib is an approved treatment, understanding its side effects is crucial for patients and healthcare providers. 3 . Vigilance for infections, proactive management of gastrointestinal issues, and careful monitoring for any skin changes are essential considerations. , 4 .

Limitations of Current Research

Research on duvelisib’s side effects is still evolving, and more comprehensive data are needed to fully understand the long-term implications and potential risks. 3 .

Future Research Directions

Future research should focus on further investigating the potential risk of increased mortality associated with duvelisib. 1 . Also, ongoing efforts should aim to identify strategies for minimizing or managing duvelisib’s side effects. 2 .

Conclusion

Duvelisib is a promising treatment option for certain types of blood cancers, but it’s important to be aware of the potential side effects. 1 , 3 . Close monitoring, preventive measures, and timely medical intervention are crucial for patients undergoing duvelisib therapy. Further research is necessary to better understand and manage the side effects of this medication. 3 .

Literature analysis of 12 papers
Positive Content
10
Neutral Content
0
Negative Content
2
Article Type
1
0
0
7
12
2.

Management of Gastro-Intestinal Toxicity of the Pi3 Kinase Inhibitor: Optimizing Future Dosing Strategies.

Author: BrealClaire, BeuvonFrederic, de Witasse-ThezyThibault, DermineSolene, Franchi-RezguiPatricia, Deau-FisherBenedicte, WillemsLise, GrignanoEric, ContejeanAdrien, BouscaryDidier, FaillieJean Luc, TreluyerJean-Marc, GuerinCorinne, ChouchanaLaurent, VignonMarguerite

Cancer treatment
Colitis

This review examines the use of phosphatidylinositol 3-kinase (PI3K) inhibitors for hematological malignancies, focusing on the incidence and toxicity of PI3K inhibitor-induced colitis. It discusses the side effects reported in clinical trials and pharmacovigilance data, and provides real-world experience in managing idelalisib-induced colitis.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

4.

PI3K Inhibitors for the Treatment of Chronic Lymphocytic Leukemia: Current Status and Future Perspectives.

Author: HusIwona, PułaBartosz, RobakTadeusz

CLL treatment
autoimmune-mediated pneumonitis
colitis
infections

Phosphoinositide 3-kinase delta (PI3Kδ) inhibitors have shown promise in treating chronic lymphocytic leukemia (CLL). Idelalisib, the first PI3Kδ inhibitor, had significant side effects. Duvelisib and umbralisib, newer PI3Kδ inhibitors, have shown improved safety profiles.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

5.

Duvelisib: a new phosphoinositide-3-kinase inhibitor in chronic lymphocytic leukemia.

Author: FrustaciAnna M, TedeschiAlessandra, DeodatoMarina, ZamprognaGiulia, CairoliRoberto, MontilloMarco

Chronic lymphocytic leukemia treatment
Immune-related effects

Duvelisib is a dual phosphoinositide-3-kinase inhibitor targeting p110-δ/γ that has been approved for relapsed/refractory chronic lymphocytic leukemia. While effective, immune-related effects often lead to treatment suspension.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

6.

Discovery of a Novel Inhaled PI3Kδ Inhibitor for the Treatment of Respiratory Diseases.

Author: ErraMontse, TaltavullJoan, BernalFrancisco Javier, CaturlaJuan Francisco, CarrascalMarta, PagèsLluís, MirMarta, EspinosaSònia, GràciaJordi, DomínguezMaría, SabatéMar, ParisStéphane, MaldonadoMónica, HernándezBegoña, BravoMónica, CalamaElena, MiralpeixMontserrat, LehnerMartin D, CalbetMarta

Cancer treatment
Improved therapeutic index
Colitis
Hepatic toxicity
Infections
Intestinal perforation
Pneumonitis
Severe diarrhea

Inhaled PI3Kδ inhibitors are being developed for the treatment of severe asthma and COPD, aiming to minimize side effects associated with oral administration.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

7.

Loss of Phosphatidylinositol 3-Kinase Activity in Regulatory T Cells Leads to Neuronal Inflammation.

Author: StarkAnne-Katrien, DavenportElizabeth C M, PattonDaniel T, ScudamoreCheryl L, VanhaesebroeckBart, VeldhoenMarc, GardenOliver A, OkkenhaugKlaus

CNS inflammation protection
Treg cell function
Immune dysregulation
Treg cell loss

PI3Kδ is crucial for Treg cell function, a type of immune cell that helps prevent autoimmune diseases. Blocking PI3Kδ can treat some cancers, but it can also cause immune problems. This study found that blocking both PI3Kα and PI3Kδ together worsened autoimmune disease in mice, highlighting the importance of PI3K signaling in immune regulation.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

8.

Isoform-Selective PI3K Inhibitors for Various Diseases.

Author: BheemanaboinaRammohan R Y

Cancer treatment
Off-target effects

Isoform-selective PI3K inhibitors have emerged as promising therapeutic agents for cancer and other diseases. These inhibitors are crucial for understanding the unique functions of each PI3K isoform and its potential therapeutic applications.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

9.

New drugs for follicular lymphoma.

Author: SorigueMarc, RiberaJosep-Maria, MotllóCristina, SanchoJuan-Manuel

Follicular lymphoma treatment
Side effects

This review explores the evidence available on new therapies for follicular lymphoma, including monoclonal antibodies, immunoconjugates, lenalidomide, bortezomib, B-cell receptor pathway inhibitors, BCL2 inhibitors, and checkpoint inhibitors. While these new drugs show promise, they also have side effects that require careful consideration.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

10.

The TKI Era in Chronic Leukemias.

Author: De NovellisDanilo, CacaceFabiana, CaprioliValeria, WierdaWilliam G, MahadeoKris M, TambaroFrancesco Paolo

CLL remission
CML remission
Improved outcomes
Side effects

Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL). TKIs like imatinib, dasatinib, and nilotinib target BCR-ABL1 in CML, while BTK inhibitors like ibrutinib and acalabrutinib target the B-cell receptor signaling pathway in CLL. These agents have improved outcomes for patients with these hematologic malignancies but may have associated side effects.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

11.

Current Treatment of Refractory/Relapsed Chronic Lymphocytic Leukemia: A Focus on Novel Drugs.

Author: SmolewskiPiotr, RobakTadeusz

CLL treatment
Drug toxicity

Treatment strategies for relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) include Bruton tyrosine kinase inhibitors, PI3K inhibitors, B-cell lymphoma 2 inhibitors, and novel CD20 monoclonal antibodies. Treatment selection depends on various factors, including prior therapy response, side effects, and comorbidities.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.